Official Conference Sponsor :
| Legal and Commercial Strategies for Combatting Generics in Pharmaceuticals | ||
| 18 January '00 - Day 1 | ||
| 08:00 | Registration and coffee |
|
| 08:30 | Opening remarks by the chair Dr. Michael L. Burstall Consultant |
|
| 08:45 | Quantifying the economic aspect of generics in Europe
- how does the increased competition from generic drugs affect healthcare
and research spending? Dr. Michael L. Burstall Consultant |
|
| 09:30 | The future of generics and reference pricing in Europe
and its implications for the industry Jim Furniss Management Consultant Cambridge Pharma Consultancy |
|
| 10:15 | Morning tea and coffee |
|
| 10:35 | Regulation and Market Development or Generics in the
United Kingdom Donald Macarthur Consultant |
|
| 11:20 | Regulation and market development of generics in Germany Wilhelm Hollenhorst Special Adviser, Healthcare System Develpment German Association of Research |
|
| 12:05 | Impact of CEE accession on research based companies and
generic competition Simon Harper Senior Assistant Solicitor Lovell White Durrant |
|
| 12:50 | Lunch |
|
| 14:00 | Analysing your most promising strategies to exploit and
extend patent protection in Europe Stephen Jones Partner Baker & McKenzie |
|
| 14:45 | Development and registration strategies which give advantage
to your branded products over generic competition Horst Kastrup Head of Drug Regulatory Affairs Asta medica |
|
| 15:45 | Afternoon tea and coffee |
|
| 16:05 | A viewpoint from the generic pharmaceutical industry Greg Perry Director General European Generics Association |
|
| 16:05 | Debating legal and commercial options to manage generic
competition and its impact on pharmaceutical companies Horst Kastrup Head of Drug Regulatory Affairs Astra Medica |
|
| 16:50 | Debating legal and commercial options to manage generic
competition and its impact on pharmaceutical companies Greg Perry Director General European Generics Association |
|
| 16:50 | Debating legal and commercial options to manage generic
competition and its impact on pharmaceutical companies Wilhelm Hollenhorst Special Adviser, Healthcare System Development Verband Forschender Arzneimettelhersteller |
|
| 17:20 | Closing remarks by the chair |
|
| 17:35 | End of Day 1 |
|
| Legal and Commercial Strategies for Combatting Generics in Pharmaceuticals | ||
| 19 January '00 - Day 2 | ||
| 08:30 | Registration and coffee |
|
| 09:00 | Opening remarks by the chair Dr Gordon Wright Director, Intellectual Property Sanofi-Synthelabo |
|
| 09:15 | Maximising the benefits of data exclusivity to defend
your product successfully Dr Christoph Hiltl Partner Boesebeck & Droste |
|
| 10:00 | New Zealand today, Europe tomorrow? - The New Zealand
Generics Programme Gisela Brinkmeier Director, International Marketing G. Pohl-Boskamp |
|
| 10:45 | Morning tea and coffee |
|
| 11:05 | Defensive pricing strategie to limit damage from generic
competition - is there a way that industry can leverage brand value Dr Jim Attridge Government and Economic Affairs AstraZeneca |
|
| 11:50 | Pros and cons of entering into the generics market Norbert Bangert Manager Generics Bayer |
|
| 12:35 | Lunch for delegates and speakers |
|
| 13:45 | Analysing the latest developments in US regulation
of generics and their effects in Europe Richard Kingham Managing Partners Covington & Burling London |
|
| 14:30 | Clarifying the impact of the Farmitalia Carlo Erba
v German patent office and BASF cases on Supplementary Protection
Certificates Lorna Brazel Senior IP solicitor Bird & Bird |
|
| 15:15 | Devising the most appropriate marketing strategies
to increase the margin of your branded products and succeed in the
emerging new marketplace Paul Jones Principal Consultant PriceWaterhouseCoopers |
|
| 16:00 | Closing remarks by the chair |
|
| 16:15 | Join us for tea and coffee to review the findings of
the conference |
|
| 16:35 | End of Conference |
|
| Legal and Commercial Strategies for Combatting Generics in Pharmaceuticals | ||
| 20 January '99 - Workshop | ||
| 08:30 | Brief outline by the workshop leaders on the issue
to be dealt with during the workshop and presentation of the studies,
2 Case Studies |
|
| 16:30 | Review and Conclusions |
|
